ATAD1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Rat brain tissue, Mouse brain tissue and Human cerebrum tissue lysates, Primary antibody: P02369(ATAD1 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 60 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02369(ATAD1 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P02369(ATAD1 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

The ATAD1 antibody is a crucial tool for studying the ATPase family AAA domain-containing protein 1 (ATAD1), also known as Thorase. ATAD1 is a mitochondrial membrane-associated AAA+ ATPase that plays a key role in regulating mitochondrial dynamics and protein homeostasis. It is involved in the disassembly of mitochondrial membrane protein complexes, particularly mediating the removal of misfolded or excess proteins, such as the AMPA receptor subunit GluA1 in neurons. This function links ATAD1 to neuroprotection and neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease.

ATAD1 antibodies are widely used in research to detect and quantify ATAD1 expression via techniques such as Western blotting, immunohistochemistry, and immunoprecipitation. They help investigate ATAD1’s interaction with substrates, its ATPase activity, and its role in mitochondrial quality control. Studies using these antibodies have revealed ATAD1’s involvement in preventing neuronal excitotoxicity by regulating glutamate receptor turnover. Knockout mouse models and cell-based assays, supported by ATAD1 antibodies, highlight its essential role in maintaining mitochondrial integrity and cellular viability. Commercially available ATAD1 antibodies are typically validated for specificity using knockout controls or siRNA-mediated knockdown. Research utilizing these tools continues to explore ATAD1’s broader implications in metabolic disorders, cancer, and aging-related pathologies.